PITTSBURGH, Oct. 17, 2022 – People with a disease characterized by lung scarring that has no obvious cause are more likely to die if they live in areas with higher levels of air pollution composed of chemicals associated with industrial sources and vehicular traffic, according to new research led by University of Pittsburgh scientists.
Credit: Goobie, et al., JAMA Internal Medicine, October 17, 2022
PITTSBURGH, Oct. 17, 2022 – People with a disease characterized by lung scarring that has no obvious cause are more likely to die if they live in areas with higher levels of air pollution composed of chemicals associated with industrial sources and vehicular traffic, according to new research led by University of Pittsburgh scientists.
The study, published today in JAMA Internal Medicine, is the first to link the chemical composition of fine particulate air pollution to worsened fibrotic interstitial lung disease (fILD) outcomes. It is also the largest study ever done to evaluate the impact of air pollution on these patients.
“Some people with these lung diseases have an expected lifespan from diagnosis to death of only a few years, and yet it’s a mystery as to why they developed the disease, why their lungs become so scarred,” said lead author Gillian Goobie, M.D., doctoral candidate in the Pitt School of Public Health’s Department of Human Genetics. “Our study points to air pollution – specifically pollutants from factories and vehicles – as potentially driving faster disease progression and premature death in these patients.”
Goobie and her team obtained data from 6,683 patients with fILDs in the U.S. and Canada and linked their home addresses with satellite and ground-monitoring air pollution data to determine air pollutant composition to an accuracy of less than half a mile.
The team specifically looked at a pollutant known as PM2.5, which refers to particulate matter that measures less than 2.5 microns across, a size invisible to the naked eye. This type of pollution is so small that it can infiltrate deep into the lungs and even cross into the blood stream, where it can contribute to other diseases outside of the lungs, such as heart disease.
“In the past, most environmental health research has focused on the simple definition of PM2.5 as anything of that size,” said co-author James Fabisiak, Ph.D., associate professor in Pitt Public Health’s Department of Environmental and Occupational Health. “But PM2.5 is chemically diverse, with a different composition depending on whether it came from a forest fire or a tailpipe. Research has lacked in determining if the type of PM2.5 matters when it comes to health effects. Our new research is a big step toward filling in that knowledge gap.”
The team found that increasing levels of PM2.5 were linked to more severe disease at diagnosis, faster disease progression as measured by lung function decline and higher likelihood of dying sooner. Pollution high in sulfate (typically produced by factories, such as the coal and steel industries), nitrate (primarily from fossil fuel combustion) and ammonium (usually produced by industry or agriculture) were associated with worse outcomes, whereas chemical signatures from more naturally occurring particulate matter – such as sea salt or soil dust – didn’t carry as high of an association.
After pollution leaves a smokestack or tailpipe, Goobie noted that sulfate- and nitrate-containing aerosols can be formed in the atmosphere from those and other gaseous pollutants and can be acidic, which can be very damaging to the tiny air sacs of the lungs.
The team is now doing laboratory studies looking at the impact of these pollutants on lung cells at the molecular level to better understand why they are particularly damaging to the lungs of certain people and whether exposure to the pollutants triggers changes to how certain genes work that could cause runaway scarring.
According to the team’s calculations, if exposure to industrial pollutants hadn’t occurred, most premature deaths among participants living in areas of North America with a heavier burden of industry – including Pittsburgh – could have been avoided. Participants of color were disproportionately exposed to higher levels of man-made air pollutants: 13% of the high-exposure group were non-white, but only 8% of the low-exposure group, highlighting the impact of environmental injustice in these findings as well.
Co-senior author S. Mehdi Nouraie, M.D., Ph.D., associate professor of pulmonary, allergy and critical care medicine at Pitt’s School of Medicine, said that the findings further emphasize the need for people with lung conditions that make them more vulnerable to pollution to pay attention to the air quality index – a forecast of air pollution – and consider minimizing time outdoors or in rooms without good air filtration during poor air quality days.
“Ultimately, we want to encourage a data-driven awareness,” Nouraie said. “We want people to think about the quality of the air we breathe. Patients, health care providers and policymakers can all use the new information we’re providing to try to improve health outcomes. When you make the air safe for the most vulnerable to breathe, you’re making it safe for all of us.”
Additional authors on this research are co-senior author Christopher J. Ryerson, M.D., M.A.S., as well as Christopher Carlsten, M.D., M.P.H., and Nasreen Khalil, M.D., all of the University of British Columbia; Kerri A. Johannson, M.D., M.P.H., of the University of Calgary; Veronica Marcoux, M.D., of the University of Saskatchewan; Deborah Assayag, M.D., of McGill University; Hélène Manganas, M.D., of the University of Montreal; Jolene H. Fisher, M.D., of the University of Toronto; Martin R. J. Kolb, M.D., Ph.D., of McMaster University; Kathleen O. Lindell, Ph.D., R.N., of the University of South Carolina; Xiaoping Chen, M.S., Kevin F. Gibson, M.D., Yingze Zhang, Ph.D., and Daniel J. Kass, M.D., all of Pitt and Pitt’s Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease at UPMC.
This was an independent, investigator-initiated study supported by Boehringer Ingelheim Pharmaceuticals Inc., which had no role in the design, analysis or interpretation of the results.
# # #
About the University of Pittsburgh School of Public Health
Founded in 1948, the University of Pittsburgh School of Public Health is a top-ranked institution of seven academic departments partnering with stakeholders locally and globally to create, implement and disseminate innovative public health research and practice. With hands-on and high-tech instruction, Pitt Public Health trains a diverse community of students to become public health leaders who counter persistent population health problems and inequities.
www.upmc.com/media
Journal
JAMA Internal Medicine
DOI
10.1001/jamainternmed.2022.4696